| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3949 | 2017 |
| Cabozantinib in patients with advanced and progressing hepatocellular carcinoma GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ... New England Journal of Medicine 379 (1), 54-63, 2018 | 2090 | 2018 |
| Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised … JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli, JW Valle, ... The Lancet 389 (10073), 1011-1024, 2017 | 1871 | 2017 |
| Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies L Marelli, R Stigliano, C Triantos, M Senzolo, E Cholongitas, N Davies, ... Cardiovascular and interventional radiology 30, 6-25, 2007 | 1051 | 2007 |
| Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma RS Finn, M Ikeda, AX Zhu, MW Sung, AD Baron, M Kudo, T Okusaka, ... Journal of Clinical Oncology 38 (26), 2960, 2020 | 921 | 2020 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of oncology 29, iv238-iv255, 2018 | 867 | 2018 |
| Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) JK Ramage, A Ahmed, J Ardill, N Bax, DJ Breen, ME Caplin, P Corrie, ... gut 61 (1), 6-32, 2012 | 686 | 2012 |
| A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability M Rodriguez-Peralvarez, TV Luong, L Andreana, T Meyer, AP Dhillon, ... Annals of surgical oncology 20, 325-339, 2013 | 614 | 2013 |
| Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma JM Llovet, T De Baere, L Kulik, PK Haber, TF Greten, T Meyer, R Lencioni Nature reviews Gastroenterology & hepatology 18 (5), 293-313, 2021 | 520 | 2021 |
| Role of tumour markers in monitoring epithelial ovarian cancer T Meyer, GJS Rustin British journal of cancer 82 (9), 1535-1538, 2000 | 441 | 2000 |
| Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind … T Meyer, R Fox, YT Ma, PJ Ross, MW James, R Sturgess, C Stubbs, ... The lancet Gastroenterology & hepatology 2 (8), 565-575, 2017 | 438 | 2017 |
| Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis G Germani, M Pleguezuelo, K Gurusamy, T Meyer, G Isgrò, AK Burroughs Journal of hepatology 52 (3), 380-388, 2010 | 402 | 2010 |
| Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II … JW Valle, H Wasan, P Johnson, E Jones, L Dixon, R Swindell, S Baka, ... British journal of cancer 101 (4), 621-627, 2009 | 359 | 2009 |
| EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization R Gillmore, S Stuart, A Kirkwood, A Hameeduddin, N Woodward, ... Journal of hepatology 55 (6), 1309-1316, 2011 | 354 | 2011 |
| A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer L Kadalayil, R Benini, L Pallan, J O'beirne, L Marelli, D Yu, A Hackshaw, ... Annals of oncology 24 (10), 2565-2570, 2013 | 353 | 2013 |
| Somatic mutation of CDKN1B in small intestine neuroendocrine tumors JM Francis, A Kiezun, AH Ramos, S Serra, CS Pedamallu, ZR Qian, ... Nature genetics 45 (12), 1483-1486, 2013 | 342 | 2013 |
| Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ... Journal of Clinical Oncology 37 (31), 2825, 2019 | 341 | 2019 |
| Mechanisms of tumour metastasis T Meyer, IR Hart European journal of cancer 34 (2), 214-221, 1998 | 315 | 1998 |
| Consensus on biomarkers for neuroendocrine tumour disease. GJ Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC ... Lancet Oncololgy 16 (9), e435-46., 2015 | 308* | 2015 |
| Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference JM Llovet, A Villanueva, JA Marrero, M Schwartz, T Meyer, PR Galle, ... Hepatology 73, 158-191, 2021 | 296 | 2021 |
Raj srirajaskanthanClinical lead Gastroenterology, King's College Hospital & Reader in Gastroenterology, Kings CollegeVerified email at nhs.net
